Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Navitas selection for a U.S. Army program to develop 10 kV silicon-carbide power semiconductors is driving attention, with traders viewing the award as defense and technology validation. The reaction is tempered by concerns that it is a development-stage project with undisclosed financial terms and no clear near-term revenue impact.

Boeing shares are under pressure after the FAA delayed 737 MAX 10 certification while reviewing a flight-management software glitch that can disrupt automated navigation in a specific landing scenario. Traders debate whether the setback signals deeper quality and leadership problems or is an overreaction to a manageable issue, with some buying the dip and others fearing further delays.

Positive Phase 3 DAYBREAK results in wet AMD drove a sharp rally: both Kodiak candidates met their primary goals, and Zenkuda showed potential for longer intervals between injections; the company plans an FDA filing. Traders celebrated the data and a possible short squeeze, while others questioned the stocks valuation and warned of profit-taking, financing needs, and remaining FDA risk.

RDDT is under pressure amid uncertainty over a potential Google AI-data licensing renewal, with traders also citing executive share sales and weak price action. The community is split between bearish calls for further declines and dip buyers who see the selloff as an opportunity.

Attention centers on Summits pending FDA decision for ivonescimab, with traders weighing its positive clinical data against uncertainty over the survival evidence regulators require. Recent concerns about cash runway and potential financing have added pressure, while some investors point to insider buying and upcoming trial catalysts as reasons for optimism.

A sharp, sustained selloff ahead of Applied Digitals upcoming fiscal first-quarter report is driving attention. Traders disagree over whether the weakness reflects broader pressure on AI data-center stocks or company-specific concerns about execution, dilution and limited updates; some are buying the dip while others are wary of the report and guidance.

HBARs sharp rally and surge in volume are being linked by traders to enterprise and AI developments, especially IBM-related integrations and Hedera council members joining NVIDIAs Open Agent Safety Platform. Some see the headlines as support for further gains, while others attribute the move to a short squeeze or speculative momentum and warn of profit-taking.

ACHR is drawing attention amid debate over Midnights development and execution: skeptics focus on the lack of a piloted transition and missed manufacturing goals, while bulls point to ongoing testing, flight tours, and the planned Boeing acquisitions as signs of progress. Some traders also attribute the stocks weakness to broader market and rate pressures.

Kodiaks positive late-stage wet AMD results have pressured OCUL as traders reassess competition for AXPAXLI. The community is split: some see Kodiaks durability data as a threat, while others argue AXPAXLIs trial results and FDA path remain stronger and view the selloff as an overreaction.

Nu Holdings is under pressure amid reports of potential talks to acquire U.K. digital bank Monzo, with traders debating whether the deal could accelerate European expansion or bring excessive cost, dilution, and execution risk. The acquisition remains unconfirmed, and some investors see the selloff as an opportunity while others oppose the move.